Reply to Fišer et al.: Myeloid reprogramming of Ph(+) B-ALL: A potential therapeutic strategy

Por Majeti, Ravindra, Dove, Christopher, McClellan, James Scott
Publicado no Proc Natl Acad Sci U S A (2015)

Genetic, Clinical, and Laboratory Markers for DOCK8 Immunodeficiency Syndrome

Por Davis, Jeremiah C., Dove, Christopher G., Su, Helen C.
Publicado em 2010

Reprogramming of primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages

Por McClellan, James Scott, Dove, Christopher, Gentles, Andrew J., Ryan, Christine E., Majeti, Ravindra
Publicado no Proc Natl Acad Sci U S A (2015)

Somatic reversion in DOCK8 immunodeficiency modulates disease phenotype

Por Jing, Huie, Zhang, Qian, Zhang, Yu, Hill, Brenna J., Dove, Christopher G., Gelfand, Erwin W., Atkinson, T. Prescott, Uzel, Gulbu, Matthews, Helen F., Mustillo, Peter J., Lewis, David B., Kavadas, Fotini D., Hanson, I. Celine, Kumar, Ashish R., Geha, Raif S., Douek, Daniel C., Holland, Steven M., Freeman, Alexandra F., Su, Helen C.
Publicado em 2014

DOCK8 regulates lymphocyte shape integrity for skin antiviral immunity

Por Zhang, Qian, Dove, Christopher G., Hor, Jyh Liang, Murdock, Heardley M., Strauss-Albee, Dara M., Garcia, Jordan A., Mandl, Judith N., Grodick, Rachael A., Jing, Huie, Chandler-Brown, Devon B., Lenardo, Timothy E., Crawford, Greg, Matthews, Helen F., Freeman, Alexandra F., Cornall, Richard J., Germain, Ronald N., Mueller, Scott N., Su, Helen C.
Publicado no J Exp Med (2014)